Display options
Cite
Poschke I, Faryna M, Bergmann F, et al. Identification of a tumor-reactive T-cell repertoire in the immune infiltrate of patients with resectable pancreatic ductal adenocarcinoma. Oncoimmunology. 2016;5(12):e1240859doi: 10.1080/2162402X.2016.1240859.
Poschke, I., Faryna, M., Bergmann, F., Flossdorf, M., Lauenstein, C., Hermes, J., Hinz, U., Hank, T., Ehrenberg, R., Volkmar, M., Loewer, M., Glimm, H., Hackert, T., Sprick, M. R., Höfer, T., Trumpp, A., Halama, N., Hassel, J. C., Strobel, O., Büchler, M., Sahin, U., & Offringa, R. (2016). Identification of a tumor-reactive T-cell repertoire in the immune infiltrate of patients with resectable pancreatic ductal adenocarcinoma. Oncoimmunology, 5(12), e1240859. https://doi.org/10.1080/2162402X.2016.1240859
Poschke, Isabel, et al. "Identification of a tumor-reactive T-cell repertoire in the immune infiltrate of patients with resectable pancreatic ductal adenocarcinoma." Oncoimmunology vol. 5,12 (2016): e1240859. doi: https://doi.org/10.1080/2162402X.2016.1240859
Poschke I, Faryna M, Bergmann F, Flossdorf M, Lauenstein C, Hermes J, Hinz U, Hank T, Ehrenberg R, Volkmar M, Loewer M, Glimm H, Hackert T, Sprick MR, Höfer T, Trumpp A, Halama N, Hassel JC, Strobel O, Büchler M, Sahin U, Offringa R. Identification of a tumor-reactive T-cell repertoire in the immune infiltrate of patients with resectable pancreatic ductal adenocarcinoma. Oncoimmunology. 2016 Oct 07;5(12):e1240859. doi: 10.1080/2162402X.2016.1240859. eCollection 2016. PMID: 28123878; PMCID: PMC5215250.
Copy Download .nbib Format: NLM
Share it on

Oncoimmunology. 2016 Oct 07;5(12):e1240859. doi: 10.1080/2162402X.2016.1240859. eCollection 2016.

Identification of a tumor-reactive T-cell repertoire in the immune infiltrate of patients with resectable pancreatic ductal adenocarcinoma.

Oncoimmunology

Isabel Poschke, Marta Faryna, Frank Bergmann, Michael Flossdorf, Claudia Lauenstein, Jennifer Hermes, Ulf Hinz, Thomas Hank, Roland Ehrenberg, Michael Volkmar, Martin Loewer, Hanno Glimm, Thilo Hackert, Martin R Sprick, Thomas Höfer, Andreas Trumpp, Niels Halama, Jessica C Hassel, Oliver Strobel, Markus Büchler, Ugur Sahin, Rienk Offringa

Affiliations

  1. Division of Molecular Oncology of Gastrointestinal Tumors, German Cancer Research Center , Heidelberg, Germany.
  2. BioNTech Diagnostics GmbH , Mainz, Germany.
  3. Department of Pathology, Heidelberg University Hospital , Heidelberg, Germany.
  4. Division of Theoretical Systems Biology, German Cancer Research Center and BioQuant Center, University of Heidelberg , Heidelberg, Germany.
  5. Department of General, Visceral and Transplantation Surgery , Heidelberg University Hospital, Heidelberg, Germany.
  6. Division of Applied Stem Cell Biology, National Center for Tumor Diseases, Heidelberg, Germany; National Center for Tumor Diseases, Department of Medical Oncology, Heidelberg University Hospital, Heidelberg, Germany.
  7. TRON - Translational Oncology at the University Medical Center of the Johannes Gutenberg University , Mainz, Germany.
  8. Division of Applied Stem Cell Biology, National Center for Tumor Diseases , Heidelberg, Germany.
  9. Division of Stem Cells and Cancer, German Cancer Research Center, Heidelberg , Germany and HI-STEM gGmbH , Heidelberg, Germany.
  10. National Center for Tumor Diseases, Department of Medical Oncology, Heidelberg University Hospital , Heidelberg, Germany.
  11. Department of Dermatology and National Center for Tumor Diseases, Heidelberg University Hospital , Heidelberg, Germany.
  12. TRON - Translational Oncology at the University Medical Center of the Johannes Gutenberg University, Mainz, Germany; BioNTech AG, Mainz, Germany.
  13. Division of Molecular Oncology of Gastrointestinal Tumors, German Cancer Research Center, Heidelberg, Germany; Department of General, Visceral and Transplantation Surgery, Heidelberg University Hospital, Heidelberg, Germany.

PMID: 28123878 PMCID: PMC5215250 DOI: 10.1080/2162402X.2016.1240859

Abstract

PURPOSE: The devastating prognosis of patients with resectable pancreatic ductal adenocarcinoma (PDA) presents an urgent need for the development of therapeutic strategies targeting disseminated tumor cells. Until now, T-cell therapy has been scarcely pursued in PDA, due to the prevailing view that it represents a poorly immunogenic tumor.

EXPERIMENTAL DESIGN: We systematically analyzed T-cell infiltrates in tumor biopsies from 127 patients with resectable PDA by means of immunohistochemistry, flow cytometry, T-cell receptor (TCR) deep-sequencing and functional analysis of

RESULTS: Prominent T-cell infiltrates, as well as tertiary lymphoid structures harboring proliferating T-cells, were detected in the vast majority of biopsies from PDA patients. The notion that the tumor is a site of local T-cell expansion was strengthened by TCR deep-sequencing, revealing that the T-cell repertoire in the tumor is dominated by highly frequent CDR3 sequences that can be up to 10,000-fold enriched in tumor as compared to peripheral blood. In fact, TCR repertoire composition in PDA resembled that in melanoma. Moreover,

CONCLUSIONS: The tumor-infiltrating T-cell response in PDA shows striking similarity to that in melanoma, where adoptive T-cell therapy has significant therapeutic impact. Our findings indicate that T-cell-based therapies may be used to counter disease recurrence in patients with resectable PDA.

Keywords: Adoptive T-cell therapy; T-cell receptor (TCR) repertoire; pancreatic ductal adenocarcinoma; tertiary lymphoid structures; tumor-infiltrating lymphocytes

References

  1. J Clin Oncol. 2008 Sep 20;26(27):4410-7 - PubMed
  2. Cell. 2015 Apr 9;161(2):205-14 - PubMed
  3. Br J Cancer. 2014 Oct 14;111(8):1469-75 - PubMed
  4. J Clin Oncol. 2015 Apr 20;33(12):1325-33 - PubMed
  5. Cancer J. 2015 Jul-Aug;21(4):299-306 - PubMed
  6. Nature. 2015 Apr 30;520(7549):692-6 - PubMed
  7. Cancer Cell. 2015 Apr 13;27(4):450-61 - PubMed
  8. Clin Cancer Res. 2014 Jan 1;20(1):44-55 - PubMed
  9. Nature. 2014 Nov 27;515(7528):568-71 - PubMed
  10. Clin Cancer Res. 2006 Sep 15;12(18):5423-34 - PubMed
  11. Science. 2014 May 9;344(6184):641-5 - PubMed
  12. N Engl J Med. 2011 May 12;364(19):1817-25 - PubMed
  13. J Immunother. 2010 Oct;33(8):828-33 - PubMed
  14. Cancer Res. 2011 Sep 1;71(17):5678-87 - PubMed
  15. Immunity. 2014 Nov 20;41(5):694-707 - PubMed
  16. Br J Cancer. 2013 Mar 5;108(4):914-23 - PubMed
  17. Cancer Immunol Immunother. 2013 Jul;62(7):1249-60 - PubMed
  18. PLoS Med. 2010 Apr 20;7(4):e1000267 - PubMed
  19. Cancer Res. 2008 Feb 1;68(3):893-900 - PubMed
  20. Clin Cancer Res. 2014 Jul 1;20(13):3422-33 - PubMed
  21. PLoS One. 2013;8(4):e60031 - PubMed
  22. Am J Pathol. 2011 Jul;179(1):37-45 - PubMed
  23. Gut. 2015 Sep;64(9):1476-84 - PubMed
  24. Cancer Immunol Immunother. 2011 Jun;60(6):809-18 - PubMed
  25. Science. 2011 Mar 25;331(6024):1612-6 - PubMed
  26. Nat Med. 2015 Jan;21(1):81-5 - PubMed
  27. N Engl J Med. 2015 Feb 19;372(8):783 - PubMed
  28. Nat Rev Immunol. 2014 Jun;14(6):377-91 - PubMed
  29. J Exp Med. 2011 Mar 14;208(3):469-78 - PubMed
  30. Cancer Res. 2011 Sep 1;71(17):5670-7 - PubMed
  31. Cancer Immunol Res. 2014 Jul;2(7):616-31 - PubMed
  32. J Pathol. 2016 Aug;239(4):450-8 - PubMed
  33. Sci Transl Med. 2014 May 28;6(238):238ra70 - PubMed
  34. Lancet Oncol. 2013 Oct;14(11):e476-85 - PubMed
  35. J Clin Invest. 2014 May;124(5):2246-59 - PubMed
  36. Proc Natl Acad Sci U S A. 2013 Dec 10;110(50):20212-7 - PubMed
  37. Nature. 2013 Aug 22;500(7463):415-21 - PubMed
  38. Science. 2015 Apr 3;348(6230):62-8 - PubMed
  39. Gastroenterology. 2013 Nov;145(5):1121-32 - PubMed
  40. Proc Natl Acad Sci U S A. 2007 Jul 17;104(29):12087-92 - PubMed
  41. Br J Cancer. 2015 May 26;112(11):1782-90 - PubMed
  42. Oncoimmunology. 2015 Sep 11;5(4):e1085147 - PubMed
  43. Science. 2015 Oct 9;350(6257):207-11 - PubMed
  44. Cancer Cell. 2015 Sep 14;28(3):273-5 - PubMed
  45. J Immunother. 2008 Oct;31(8):742-51 - PubMed
  46. Mol Oncol. 2015 Dec;9(10):1918-35 - PubMed
  47. PLoS One. 2009 Nov 16;4(11):e7847 - PubMed
  48. Science. 2015 Apr 3;348(6230):69-74 - PubMed
  49. J Immunother. 2015 Jan;38(1):1-11 - PubMed
  50. Science. 2015 Dec 11;350(6266):1387-90 - PubMed
  51. Cancer Immunol Immunother. 2014 Oct;63(10):1061-71 - PubMed
  52. Ann Surg. 2011 Aug;254(2):311-9 - PubMed
  53. Pancreas. 2004 Jan;28(1):e26-31 - PubMed
  54. N Engl J Med. 2012 Jun 28;366(26):2455-65 - PubMed

Publication Types